Based on the crawled pages, the Innovestor Life Science Fund invests in a variety of companies, with a strong focus on digital health and medtech. They seem to prioritize B2B business models, although they also have some B2C investments. The fund's portfolio includes companies from various sectors including Software & SaaS, Digital Commerce, Industry 4.0, and Therapeutics, indicating a broad interest within the life science and related technology spaces. The fund considers companies across different stages, as evidenced by investments dating back to 2016 and as recent as 2025. They look for companies with strong potential, as evidenced by their investment in Alex Therapeutics, highlighted by its co-development DTx business model, strong RCT results, and FDA Breakthrough Designation. The fund also appears to have a global outlook, investing in companies based in Finland, Sweden, and Lithuania. Specific rationale for investments are sometimes provided, highlighting key factors such as innovative business models, strong clinical data, and market potential. This suggests a due diligence process that goes beyond just the basic metrics and considers the underlying scientific and commercial viability of each investment. The portfolio companies suggest a focus on companies leveraging technology to improve healthcare delivery, diagnostics, and therapeutic development. This includes remote medical examinations, AI-powered solutions, digital therapeutics, and advanced diagnostics. The fund seems to be actively seeking out companies with innovative technologies that can address unmet needs in the healthcare industry. Overall, the Innovestor Life Science Fund appears to be a diversified fund that is focused on investing in innovative companies in the life science and related technology sectors. The fund has a global outlook and is willing to invest in companies at various stages of development. The fund is actively seeking out companies with innovative technologies that can address unmet needs in the healthcare industry.
Preferred startup development maturity for initial funding deployment.
Digital Health, Medtech, Therapeutics, Software & SaaS, Digital Commerce, Industry 4.0
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...